Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC

Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research Business

Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer

Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA biomarkers

Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD

Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD…


Artificial_Intelligence

AI in Healthcare and Digital Health Video Recap —December 2, 2025

Here’s your biweekly AI in Healthcare and Digital Health video brief covering…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Protego Biopharma $130M Series B

Lucid Diligence Brief: Protego Biopharma $130M Series B Professional audiences…


Artificial_Intelligence

AI in Healthcare and Digital Health Today—December 1, 2025

This week's AI in Healthcare and Digital Health update highlights…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen collaboration

Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer

Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration

Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Waker BioScience Series A in CGT

Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…


Privacy Preference Center